/PRNewswire/ MedRhythms announced the successful completion of a multi-site feasibility study of MR-005, its investigational asset in development for the.
/PRNewswire/ MedRhythms announced today that the company s pivotal trial for MR-001, a novel digital intervention in development to treat gait deficits in.
NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it has initiated a Phase 2 dose-finding